Study on safty of standardized specific mite-allergen immunotherapy to children with allergic rhinitis and/or asthma.
- Author:
Yabin WU
1
;
Zhen LONG
;
Yang HUANG
;
Xuanzhao HUANG
Author Information
1. Department of Pediatric Internal Immunotherapy Centre, Hubei Maternal and Child Health Hospital, Wuhan 430071, China. wuyabin458@sohu.com
- Publication Type:Clinical Trial
- MeSH:
Adolescent;
Animals;
Asthma;
immunology;
therapy;
Child;
Child, Preschool;
Desensitization, Immunologic;
adverse effects;
standards;
Dose-Response Relationship, Immunologic;
Female;
Humans;
Hypersensitivity, Immediate;
Male;
Mites;
immunology;
Rhinitis, Allergic, Perennial;
immunology;
therapy
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2011;25(14):641-644
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the adverse reaction of standardized specific mite-allergen immunotherapy.
METHOD:One hundred and fifty-two patients diagnosed by the pediatric immunotherapy center of our hospital were treated with increasing doses of standardized specific mite-allergen injection. Before and 30 minutes after treatment, the peak expiratory flow (PEF) and pulmonary function for the maximum lung ventilation function were checked, and the adverse reactions were recorded.
RESULT:Six hundred and eighty-one injections were recorded. 84 injections (12.3%) caused immediate side effects, including 64 mild local adverse reactions (9.4%), 2 moderate local adverse reactions (0.3%), 18 systemic adverse reactions (2.6%) which were mild asthma, and no fatal anaphylactic shock and other serious adverse reactions were found. 50 injections (7.3%) cased delayed adverse reactions, all of which were mild local adverse reactions. The rate of immediate local adverse reactions and systemic adverse reactions in the maintenance treatment period was significantly higher than that in the initial treatment period (chi2 = 4.59, 19.82 respectively; P < 0.05, < 0.01 respectively). The rate of delayed adverse reactions was no significant differences (chi2 = 2.30; P > 0.05). The PEF change rate (-0.000 2 +/- 0.085 9) of the children at 681 injections and the MMEF change rate of the children at 109 injections (0.275 +/- 0.206) were not statistically different (t = -0.047, 1.39; P = 0.963, 0.166).
CONCLUSION:Standardized specific mite-allergen immunotherapy is safe for children with allergic rhinitis and/or asthma.
